G1 Therapeutics Stock Shares Outstanding
| GTHX Stock | USD 3.99 0.13 3.37% |
G1 Therapeutics fundamentals help investors to digest information that contributes to G1 Therapeutics' financial success or failures. It also enables traders to predict the movement of GTHX Stock. The fundamental analysis module provides a way to measure G1 Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to G1 Therapeutics stock.
Common Stock Shares Outstanding is likely to drop to about 33.7 M in 2024. GTHX | Shares Outstanding |
G1 Therapeutics Company Shares Outstanding Analysis
G1 Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current G1 Therapeutics Shares Outstanding | 52.2 M |
Most of G1 Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, G1 Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
GTHX Shares Outstanding Driver Correlations
Understanding the fundamental principles of building solid financial models for G1 Therapeutics is extremely important. It helps to project a fair market value of GTHX Stock properly, considering its historical fundamentals such as Shares Outstanding. Since G1 Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of G1 Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of G1 Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
GTHX Shares Outstanding Historical Pattern
Today, most investors in G1 Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various G1 Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of G1 Therapeutics shares outstanding as a starting point in their analysis.
G1 Therapeutics Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
GTHX Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, G1 Therapeutics has 52.2 M of shares currently outstending. This is 71.09% lower than that of the Biotechnology sector and 51.15% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 90.87% higher than that of the company.
GTHX Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses G1 Therapeutics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of G1 Therapeutics could also be used in its relative valuation, which is a method of valuing G1 Therapeutics by comparing valuation metrics of similar companies.G1 Therapeutics is currently under evaluation in shares outstanding category among related companies.
G1 Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of G1 Therapeutics from analyzing G1 Therapeutics' financial statements. These drivers represent accounts that assess G1 Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of G1 Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 991.1M | 681.4M | 428.2M | 236.9M | 157.8M | 149.9M | |
| Enterprise Value | 732.1M | 501.9M | 290.1M | 226.1M | 182.7M | 173.5M |
GTHX Fundamentals
| Return On Equity | -0.92 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.58) % | ||||
| Operating Margin | (0.60) % | ||||
| Current Valuation | 183.29 M | ||||
| Shares Outstanding | 52.2 M | ||||
| Shares Owned By Insiders | 11.65 % | ||||
| Shares Owned By Institutions | 30.03 % | ||||
| Number Of Shares Shorted | 2.42 M | ||||
| Price To Earning | (1.95) X | ||||
| Price To Book | 6.71 X | ||||
| Price To Sales | 2.88 X | ||||
| Revenue | 82.51 M | ||||
| Gross Profit | 47.55 M | ||||
| EBITDA | (39.01 M) | ||||
| Net Income | (47.97 M) | ||||
| Cash And Equivalents | 143.96 M | ||||
| Cash Per Share | 3.37 X | ||||
| Total Debt | 57.17 M | ||||
| Debt To Equity | 1.24 % | ||||
| Current Ratio | 4.75 X | ||||
| Book Value Per Share | 0.68 X | ||||
| Cash Flow From Operations | (38.34 M) | ||||
| Short Ratio | 2.73 X | ||||
| Earnings Per Share | (0.93) X | ||||
| Target Price | 8.5 | ||||
| Number Of Employees | 100 | ||||
| Beta | 1.7 | ||||
| Market Capitalization | 208.28 M | ||||
| Total Asset | 121.54 M | ||||
| Retained Earnings | (779.99 M) | ||||
| Working Capital | 85.23 M | ||||
| Current Asset | 252.33 M | ||||
| Current Liabilities | 9.86 M | ||||
| Net Asset | 121.54 M |
About G1 Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze G1 Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of G1 Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of G1 Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards G1 Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, G1 Therapeutics' short interest history, or implied volatility extrapolated from G1 Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out G1 Therapeutics Piotroski F Score and G1 Therapeutics Altman Z Score analysis. For more information on how to buy GTHX Stock please use our How to Invest in G1 Therapeutics guide.Note that the G1 Therapeutics information on this page should be used as a complementary analysis to other G1 Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for GTHX Stock analysis
When running G1 Therapeutics' price analysis, check to measure G1 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy G1 Therapeutics is operating at the current time. Most of G1 Therapeutics' value examination focuses on studying past and present price action to predict the probability of G1 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move G1 Therapeutics' price. Additionally, you may evaluate how the addition of G1 Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |
Is G1 Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of G1 Therapeutics. If investors know GTHX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about G1 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.93) | Revenue Per Share 1.595 | Quarterly Revenue Growth 0.451 | Return On Assets (0.16) | Return On Equity (0.92) |
The market value of G1 Therapeutics is measured differently than its book value, which is the value of GTHX that is recorded on the company's balance sheet. Investors also form their own opinion of G1 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is G1 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because G1 Therapeutics' market value can be influenced by many factors that don't directly affect G1 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between G1 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if G1 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, G1 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.